Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Lorlatinib Continuation Study
NCT05144997 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this protocol is to provide continued treatment access and safety follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer sponsored lorlatinib parent studies that will be closed. Additional follow-up safety data collection will permit further characterization of the safety profile of lorlatinib in participants continuing to receive study intervention
Conditions Studied
Interventions
- DRUG Lorlatinib
Study Locations (20)
Zhejiang
- The First Affiliated Hospital Zhejiang University School of Medicine — Hangzhou
- Zhejiang Cancer Hospital — Hangzhou
- The Second Affiliated Hospital of Zhejiang University College of Medicine — Hangzhou
Other
- Fudan University Shanghai Cancer Center — Shanghai
- CHU de Rennes - Hôpital Pontchaillou — Rennes
- Institut Gustave Roussy — Villejuif
Beijing Municipality
- Beijing Chest Hospital, Capital Medical University — Beijing
- Beijing Cancer Hospital — Beijing
Jilin
- Jilin Cancer Hospital — Changchun
- The first hospital of jilin university — Changchun
California
- Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine
Anhui
- The First affiliated Hospital of Anhui Medical University — Hefei
Fujian
- Fujian Cancer Hospital — Fuzhou
Guangdong
- Guangdong Provincial People's Hospital — Guangzhou
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2021-12-28 |
| Est. Completion | 2026-12-28 |
| Phase | Phase 4 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05144997
The ClinicalTrials.gov registry entry for NCT05144997 describes a study currently listed as active not recruiting. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with NSCLC appearing as the primary indexed condition, and to 1 intervention — of which Lorlatinib is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05144997 reports 20 study locations spanning 14 distinct geographic areas — top geographies include Zhejiang, Other, Beijing Municipality. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05144997 about?
NCT05144997 is a clinical study titled "Lorlatinib Continuation Study". The purpose of this protocol is to provide continued treatment access and safety follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer sponsored lorlatinib parent studies that will be closed. Additional follow-up safety data collection will permit...
What is the current status of trial NCT05144997?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 76 participants. The study started on 2021-12-28. Estimated completion is 2026-12-28.
What conditions does trial NCT05144997 study?
This clinical trial studies the following conditions: NSCLC, Non-Small-Cell Lung Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05144997?
The interventions under investigation include: Lorlatinib (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05144997?
This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05144997 being conducted?
This trial has 20 study locations across California, Anhui, Beijing Municipality, Fujian, Guangdong. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.